GRAIL (GRAL) Projected to Post Earnings on Thursday

GRAIL (NASDAQ:GRAL) will likely be releasing its Q4 2025 results before the market opens on Thursday, February 19th. Analysts expect the company to announce earnings of ($3.33) per share for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, February 20, 2026 at 4:00 PM ET.

GRAIL (NASDAQ:GRAL) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($2.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.40) by $0.94. GRAIL had a negative net margin of 286.43% and a negative return on equity of 15.69%. The business had revenue of $36.19 million during the quarter, compared to the consensus estimate of $33.83 million. On average, analysts expect GRAIL to post $-15 EPS for the current fiscal year and $-13 EPS for the next fiscal year.

GRAIL Stock Performance

GRAL opened at $100.40 on Thursday. The stock has a market capitalization of $3.91 billion, a PE ratio of -8.63 and a beta of 4.52. GRAIL has a one year low of $20.44 and a one year high of $118.84. The business’s 50 day moving average price is $97.41 and its 200 day moving average price is $73.40.

Hedge Funds Weigh In On GRAIL

Several institutional investors have recently modified their holdings of GRAL. Bank of America Corp DE raised its stake in shares of GRAIL by 121.0% in the third quarter. Bank of America Corp DE now owns 335,365 shares of the company’s stock valued at $19,830,000 after acquiring an additional 183,611 shares in the last quarter. Invesco Ltd. grew its stake in GRAIL by 259.1% during the 2nd quarter. Invesco Ltd. now owns 218,671 shares of the company’s stock worth $11,244,000 after purchasing an additional 157,780 shares in the last quarter. Franklin Resources Inc. increased its holdings in GRAIL by 3,072.7% during the 4th quarter. Franklin Resources Inc. now owns 146,135 shares of the company’s stock worth $12,508,000 after purchasing an additional 141,529 shares during the period. UBS Group AG raised its position in GRAIL by 54.2% in the 3rd quarter. UBS Group AG now owns 360,456 shares of the company’s stock valued at $21,314,000 after purchasing an additional 126,738 shares in the last quarter. Finally, Squarepoint Ops LLC purchased a new position in shares of GRAIL in the 3rd quarter valued at about $6,643,000.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on GRAL. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of GRAIL in a research note on Thursday, January 22nd. Morgan Stanley upped their target price on shares of GRAIL from $85.00 to $110.00 and gave the company an “equal weight” rating in a research report on Monday, December 1st. Guggenheim increased their target price on shares of GRAIL from $100.00 to $130.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Finally, Canaccord Genuity Group lifted their price target on shares of GRAIL from $85.00 to $105.00 and gave the company a “buy” rating in a research report on Monday, November 17th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $105.00.

About GRAIL

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.